ConductScience.org, home

Comparison · NCT03325881-cb6fb970

SHP465 vs Placebo: Number of Participants With Clinically Significant Change in Clinical Laboratory Test Results Assessed by the Investigator

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. SHP465 vs Placebo: Number of Participants With Clinically Significant Change in Clinical Laboratory Test Results Assessed by the Investigator. Trial comparisons, record NCT03325881-cb6fb970. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03325881-cb6fb970

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0787wilson
Risk in group 2000.082wilson
Risk difference, group 1 minus group 20-0.0820.0787newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1SHP465Participants received 6.25 mg SHP465 capsule orally once daily for 4 weeks.045OG001
Group 2PlaceboParticipants received placebo matched to SHP465 capsule orally once daily for 4 weeks.043OG000

Outcome

Type
SECONDARY
Title
Number of Participants With Clinically Significant Change in Clinical Laboratory Test Results Assessed by the Investigator
Description
Clinical laboratory tests included biochemistry, endocrinology, hematology and urinalysis. The investigator assessed out-of-range clinical laboratory values for clinical significance, if the value(s) were not clinically significant or clinically significant.
Time frame
From start of study drug administration up to follow-up (Week 5)
Population
Safety set consisted of all participants in the randomized set who taken at least 1 dose of investigational product.

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
NCT number
NCT03325881
Phases
PHASE3
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465, Placebo
Lead sponsor
Shire
Results first posted
2019-08-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03325881-cb6fb970